

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074750 A1

(51) International Patent Classification⁷: **C07D 233/78**,
401/12, 403/12, 405/12, A61K 31/4166, 31/454, 31/4439,
A61P 35/00, 11/00, 19/00, 29/00

(21) International Application Number: PCT/SE02/00475

(22) International Filing Date: 13 March 2002 (13.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0100902-6 15 March 2001 (15.03.2001) SE
0100903-4 15 March 2001 (15.03.2001) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ERIKSSON, Anders** [SE/SE]; AstraZeneca R & D, S-221 87 Lund (SE). **LEPISTÖ, Matti** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **LUNDKVIST, Michael** [SE/SE]; AstraZeneca R & D, S-221 87 Lund (SE). **MUNCK AF ROSENSCHÖLD, Magnus** [SE/SE]; AstraZeneca R & D, S-221 87 Lund (SE). **ZLATOIDSKY, Pavol** [SK/SE]; AstraZeneca R & D, S-221 87 Lund (SE).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY ASTRAZENECA AB**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METALLOPROTEINASE INHIBITORS

(57) Abstract: The invention provides a metalloproteinase inhibitor compound comprising a metal binding group having formula (I), for use in the treatment of a disease or condition mediated by one or more metalloproteinase enzymes wherein X is selected from NR1, O, S; B is C or CH, Y1 and Y2 are independently selected from O, S; R1 is selected from H, alkyl, haloalkyl.



WO 02/074750 A1